Drug Profile
Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics
Alternative Names: ATA 190; Autologous ATA188; Autologous ATA190; Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics; EBV-CTL - Atara BiotherapeuticsLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Atara Biotherapeutics; Memorial Sloan-Kettering Cancer Center
- Developer QIMR Berghofer Medical Research Institute
- Class Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (Parenteral)
- 31 Mar 2019 Phase-I development is ongoing in USA
- 28 Feb 2019 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (Parenteral)